private:cartiva
|
3508650
|
May 23rd, 2019 12:00AM
|
Cartiva, Inc.
|
1.4K
|
45.00
|
Open
|
Medical Devices
|
May 23rd, 2019 11:39AM
|
May 23rd, 2019 11:39AM
|
Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder.
Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates.
|
Open
|
|
Open
|
Windward Pkwy
|
Alpharetta
|
GA
|
US
|
30005
|
|
Cartiva
|
|
Health Care Equipment & Services
|
private:cartiva
|
3508650
|
Feb 17th, 2018 12:00AM
|
Cartiva, Inc.
|
966
|
34.00
|
Open
|
Medical Devices
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder. Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates.
|
|
|
|
|
|
|
|
|
|
Cartiva
|
|
Health Care Equipment & Services
|
private:cartiva
|
3508650
|
Feb 16th, 2018 12:00AM
|
Cartiva, Inc.
|
966
|
34.00
|
Open
|
Medical Devices
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder.
Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates.
|
|
|
|
|
|
|
|
|
|
Cartiva
|
|
Health Care Equipment & Services
|
private:cartiva
|
3508650
|
Feb 15th, 2018 12:00AM
|
Cartiva, Inc.
|
966
|
34.00
|
Open
|
Medical Devices
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder.
Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates.
|
|
|
|
|
|
|
|
|
|
Cartiva
|
|
Health Care Equipment & Services
|
private:cartiva
|
3508650
|
Feb 14th, 2018 12:00AM
|
Cartiva, Inc.
|
966
|
34.00
|
Open
|
Medical Devices
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder.
Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates.
|
|
|
|
|
|
|
|
|
|
Cartiva
|
|
Health Care Equipment & Services
|
private:cartiva
|
3508650
|
Feb 13th, 2018 12:00AM
|
Cartiva, Inc.
|
966
|
34.00
|
Open
|
Medical Devices
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder.
Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates.
|
|
|
|
|
|
|
|
|
|
Cartiva
|
|
Health Care Equipment & Services
|
private:cartiva
|
3508650
|
Feb 12th, 2018 12:00AM
|
Cartiva, Inc.
|
966
|
34.00
|
Open
|
Medical Devices
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder.
Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates.
|
|
|
|
|
|
|
|
|
|
Cartiva
|
|
Health Care Equipment & Services
|
private:cartiva
|
3508650
|
Feb 11th, 2018 12:00AM
|
Cartiva, Inc.
|
966
|
34.00
|
Open
|
Medical Devices
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder.
Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates.
|
|
|
|
|
|
|
|
|
|
Cartiva
|
|
Health Care Equipment & Services
|
private:cartiva
|
3508650
|
Feb 10th, 2018 12:00AM
|
Cartiva, Inc.
|
966
|
34.00
|
Open
|
Medical Devices
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder.
Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates.
|
|
|
|
|
|
|
|
|
|
Cartiva
|
|
Health Care Equipment & Services
|
private:cartiva
|
3508650
|
Feb 9th, 2018 12:00AM
|
Cartiva, Inc.
|
966
|
34.00
|
Open
|
Medical Devices
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder.
Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates.
|
|
|
|
|
|
|
|
|
|
Cartiva
|
|
Health Care Equipment & Services
|